返回 Agenda
[V7-S3] Various Initiatives after Marketing of Regenerative Medical Products
Session Chair(s)
Yoji Sato, PHD
Deputy Director General, National Institute of Health Sciences, Japan
Currently 4 products are approved for regenerative medicine and other products, moreover, efforts are underway for various research and business development. In this session, we need to understand the outline of the National Consortium established by the Society of Regenerative Medicine, explain the status of support at the academic society and the data registration system and the patient registration system. We discuss the future issues and expectations by asking their opinions from each point of view on issues and expected outcome from databases and ongoing operations.
Speaker(s)
Kazuhisa Koike, PHD
Office of Medical Devices, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Safety Measures for Regenerative Medical Products in PMS
Mariko Okada, DVM
Director, PV, JCR Pharmaceutical Co., Ltd., Japan
Collaboration with Academia for Patient Registration System from Industry Standpoint
Kiyoshi Okada, MD, PHD
Professor , Deputy Director, Regenerative Medicine Support Office, Future Medica, the University of Osaka & the University of Osaka Hospital, Japan
Outline of Regenerative Medical National Consortium